Literature DB >> 30221696

LIMD2 targeted by miR‑34a promotes the proliferation and invasion of non‑small cell lung cancer cells.

Fei Wang1, Zhaoguo Li2, Lei Xu3, Yongchao Li1, Yi Li1, Xingbo Zhang4, Yue Wang5, Dazhong Liu1.   

Abstract

A previous study indicated that LIM domain containing 2 (LIMD2) is an oncogene in a variety of human cancers, including breast, bladder and thyroid cancers, and melanoma; however, the role of LIMD2 in non‑small cell lung cancer (NSCLC) remains largely unknown. In the present study, by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) analysis, it was demonstrated that LIMD2 was significantly upregulated in NSCLC tissues compared with adjacent normal tissues. Consistently, LIMD2 was also upregulated in NSCLC cell lines. Furthermore, the present study reported that knockdown of LIMD2 significantly inhibited the proliferation and invasion of H1299 and A549 cells by Cell Counting Kit‑8 and Transwell assays. In addition, the expression of LIMD2 was determined to be regulated by microRNA (miR)‑34a in the present study. RT‑qPCR and western blot analysis indicated that overexpression of miR‑34a notably reduced the mRNA and protein expression levels of LIMD2 in H1299 and H549 cells. Additionally, the present study reported an inverse correlation between the expression of LIMD2 and miR‑34a in NSCLC tissues. A luciferase reporter assay also demonstrated that miR‑34a directly targeted the mRNA expression of LIMD2 in NSCLC cells. Finally, miR‑34a was revealed to possess a tumor suppressive role in NSCLC cells. Collectively, the results of the present study revealed that LIMD2 promoted NSCLC progression and was regulated by miR‑34a.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30221696     DOI: 10.3892/mmr.2018.9464

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.

Authors:  Ran Xiong; Xiang-Xiang Sun; Han-Ran Wu; Guang-Wen Xu; Gao-Xiang Wang; Xiao-Hui Sun; Mei-Qing Xu; Ming-Ran Xie
Journal:  Thorac Cancer       Date:  2019-11-27       Impact factor: 3.500

2.  LIMD2 Regulates Key Steps of Metastasis Cascade in Papillary Thyroid Cancer Cells via MAPK Crosstalk.

Authors:  Rodrigo Pinheiro Araldi; Thatiana Correa de Melo; Débora Levy; Dener Madeiro de Souza; Beatriz Maurício; Gabriel Avelar Colozza-Gama; Sergio Paulo Bydlowski; Hongzhuang Peng; Frank J Rauscher; Janete Maria Cerutti
Journal:  Cells       Date:  2020-11-23       Impact factor: 6.600

3.  MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation.

Authors:  Jolien De Wyn; Mark W Zimmerman; Nina Weichert-Leahey; Carolina Nunes; Belamy B Cheung; Brian J Abraham; Anneleen Beckers; Pieter-Jan Volders; Bieke Decaesteker; Daniel R Carter; Alfred Thomas Look; Katleen De Preter; Wouter Van Loocke; Glenn M Marshall; Adam D Durbin; Frank Speleman; Kaat Durinck
Journal:  Cancers (Basel)       Date:  2021-09-24       Impact factor: 6.575

4.  Low-Dose Apatinib Improves the Prognosis of Patients with Recurrent High-Grade Gliomas.

Authors:  Ming Zhang; Liying Gao; Xiaofeng Liu; Fang Dong; Qun Su; Yanping Zhang; Fengju Li; Hulan Wang; Pengbing Han
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-05       Impact factor: 2.650

5.  Knockdown of Thymidine Kinase 1 Suppresses Cell Proliferation, Invasion, Migration, and Epithelial-Mesenchymal Transition in Thyroid Carcinoma Cells.

Authors:  Chang Liu; Jian Wang; Li Zhao; Hui He; Pan Zhao; Zheng Peng; Feiyuan Liu; Juan Chen; Weiqing Wu; Guangsuo Wang; Fajin Dong
Journal:  Front Oncol       Date:  2020-01-29       Impact factor: 6.244

6.  An interactive network of alternative splicing events with prognostic value in geriatric lung adenocarcinoma via the regulation of splicing factors.

Authors:  Yidi Wang; Yaxuan Wang; Kenan Li; Yabing Du; Kang Cui; Pu Yu; Tengfei Zhang; Hong Liu; Wang Ma
Journal:  Biosci Rep       Date:  2020-10-30       Impact factor: 3.840

7.  LIM domain-containing 2 (LIMD2) promotes the progress of ovarian cancer via the focal adhesion signaling pathway.

Authors:  Lixin Chen; Ji Qian; Qinghua You; Jie Ma
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.